Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?

Tigen K., Cevik C.

CURRENT PHARMACEUTICAL DESIGN, vol.16, no.26, pp.2866-2871, 2010 (SCI-Expanded) identifier

  • Publication Type: Article / Review
  • Volume: 16 Issue: 26
  • Publication Date: 2010
  • Doi Number: 10.2174/138161210793176473
  • Journal Name: CURRENT PHARMACEUTICAL DESIGN
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2866-2871
  • Keywords: Dilated Cardiomyopathy, Beta-blocker Therapy, CHRONIC HEART-FAILURE, OBSTRUCTIVE PULMONARY-DISEASE, LEFT-VENTRICULAR DYSFUNCTION, CARDIOVASCULAR DRUG-THERAPY, LONG-TERM TREATMENT, ELDERLY-PATIENTS, ATRIAL-FIBRILLATION, ADRENERGIC-BLOCKADE, DOUBLE-BLIND, RETROSPECTIVE ANALYSIS
  • Marmara University Affiliated: No

Abstract

Among the multiple pharmacologic and non-pharmacologic therapies, beta-blockers seem to be the mainstay of heart failure management. Although the first large studies failed to demonstrate a significant improvement in mortality, the results from subsequent studies revealed significant risk reductions in mortality with metoprolol, carvedilol and bisoprolol. Decision of the appropriate therapeutic agent depends on the existence of some specific conditions complicating dilated cardiomyopathy. This article reviews the impact of beta-blocker therapy in patients with dilated cardiomyopathy of ischemic or non-ischemic etiology.